Recent studies indicate that the type 2 cannabinoid receptors () have become an attractive target for treating a variety of pathologies, including cancers, neurodegenerative diseases, inflammation, pain, osteoporosis, immunological disorders and drug abuse. In addition, it appears that many of these diseases have up-regulated expression. However, the precise role of in the regulation of diseases remains unclear. The ability to specifically image would contribute to develop reliable -based therapeutic approaches with a better understanding of the mechanism of action in these diseases. We developed a -targeted zwitterionic near-infrared (NIR) fluorescent probe, ZW760-mbc94. When compared with a previously reported probe (NIR760-mbc94) with the same targeting moiety but a charged NIR fluorescent dye, ZW760-mbc94 showed improved binding specificity in vitro and ex vivo. Overall, ZW760-mbc94 appears to have great potential as a -targeted contrast agent.